Clinical comparison of omicron and delta variants in older COVID-19 patients and the effect of vaccination status

Abstract

Aim: It was aimed to investigate the clinical course of the Omicron vand Delta variant among the SARS-CoV-2 vaccinated and unvaccinated COVID-19 patients over 65 years old and to compare their effects on patients. Material and Method: The study was conducted on 567 COVID-19 patients over 65 years old. All patients’ gender, age, medical history, COVID-19 PCR test results, blood test results, thorax CT images, vaccination status, hospitalization status, and treatment results were recorded. When evaluating the chest CT images, a semiquantitative scoring system was used. The patients were divided into the Omicron and Delta variant subgroups, and vaccinated and unvaccinated groups. Comparisons were made between the Delta variant and Omicron variant groups, the vaccinated and unvaccinated patient groups,and SARS-CoV-2 mRNA vaccinated and inactivated SARS-CoV-2 vaccinated patient groups. Results: A total of 519 patients were included in the study.337 patients were in the Omicron variant group, 182 were in the Delta variant group.The hospitalization rate, ICU admission rate, mortality rate, rate of symptomatic patients,and the median thorax CT severity score was significantly higher in the Delta variant group than the Omicron variant group.The hospitalization rate, ICU admission rate, mortality rate, median thorax CT score and the rate of asymptomatic patients was significantly higher in the unvaccinated patient group than in the vaccinated group.There was no significant difference in the mortality rates and in the ICU admission rates between the inactivated SARS-CoV-2 vaccinated group and the SARS-CoV-2 mRNA vaccinated group. Conclusion: The SARS-CoV-2 Omicron variant compared to the Delta variant and the SARS-CoV-2 vaccinated patients compared to the unvaccinated patients had a milder clinical course and less mortality in COVID-19 patients over 65 years old.

Keywords

• Chest CT
• COVID-19
• delta variant
• older patients
• omicron variant
• SARS-CoV-2 vaccine

References

1. WHO Coronavirus (COVID-19) Dashboard https: //covid19.who.int/ Accessed 03 March 2022.
2. Güven BB, Ertürk T, Yıldız E, Durmayüksel E , Ersoy A, Tanoğlu A. Our convalescent plasma experiences in COVID-19 patients hospitalized in the intensive care unit. J Health Sci Med 2022; 5: 600-6.
3. Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19: 409–24.
4. He X, Hong W, Pan X, Lu G, Wei X. SARS-CoV-2 Omicron variant: Characteristics and prevention. MedComm 2020; 2: 838-45.
5. SARS-CoV-2 Variant Classifications and Definitions - CDC (Centers for Disease Control and Prevention). https: //www.cdc.gov/coronavirus/2019-ncov/variants/variant-classifications.html Accessed 03 March 2022
6. Tracking SARS-CoV-2 variants – WHO. https: //www.who.int/en/activities/tracking-SARS-CoV-2-variants/ Accessed 07 March 2022
7. Araf Y, Akter F, Tang YD, et al. Omicron variant of SARS-CoV-2: Genomics, transmissibility, and responses to current COVID-19 vaccines. J Med Virol 2022; 94: 1825-32.
8. Kumar S, Thambiraja TS, Karuppanan K, Subramaniam G. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol 2022; 94: 1641-9.

9. Pan F, Ye T, Sun P, et al. Time course of lung changes at chest CT during recovery from coronavirus disease 2019 (COVID-19). Radiology 2020; 295: 715-21.
10. Francone M, Iafrate F, Masci GM, et al. Chest CT score in COVID-19 patients: correlation with disease severity and short-term prognosis. Eur Radiol 2020; 30: 6808-17.
11. Poutanen SM. Human Coronaviruses. Principles and Practice of Pediatric Infectious Diseases 2012; 1117-20.
12. Scialo F, Daniele A, Amato F, et al. ACE2: The major cell entry receptor for SARS-CoV-2. Lung 2020; 198: 867-77.
13. Mahase E. COVID-19: Hospital admission 50-70% less likely with omicron than delta, but transmission a major concern. BMJ 2021; 375: n3151.
14. Christie B. COVID-19: Early studies give hope omicron is milder than other variants. BMJ 2021; 375: n3144.
15. Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet 2022; 399: 437-46.
16. Kahn F, Bonander C, Moghaddassi M, et al. Risk of severe COVID-19 from the Delta and Omicron variants in relation to vaccination status, sex, age and comorbidities - surveillance results from southern Sweden, July 2021 to January 2022. Euro Surveill 2022; 27.
17. Bentley EG, Kirby A, Sharma P, et al. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. bioRxiv 2021.12.26.474085
18. Quach C, Blanchard AC, Lamarche J, Audy N, Lamarre V. Should healthcare workers with SARS-CoV-2 household exposures work? A Cohort Study. medRxiv 2022.01.23.22269719.
19. Al Kaabi N, Zhang Y, Xia S, et al. Effect of 2 inactivated SARS-CoV-2 vaccines on symptomatic COVID-19 infection in adults: a randomized clinical trial. JAMA 2021; 326: 35-45.
20. Chagla Z. The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. Ann Intern Med 2021; 174: JC15.
21. Lopez Bernal J, Andrews N, Gower C, et al. Effectiveness of the Pfizer-BioNTech and Oxford-AstraZeneca vaccines on covid-19 related symptoms, hospital admissions, and mortality in older adults in England: test negative case-control study. BMJ 2021; 373: n1088.
22. Ozcelik F, Tanoglu A, Guven BB, Keskin U, Kaplan M. Assessment of severity and mortality of COVID-19 with anti-A1 and anti-B IgM isohaemagglutinins, a reflection of the innate immune status. Int J Clin Pract 2021; 75: e14624.
23. Lim WW, Mak L, Leung GM, Cowling BJ, Peiris M. Comparative immunogenicity of mRNA and inactivated vaccines against COVID-19 Lancet Microbe 2021; 2: e423.